Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: Results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer

Quality of Life Research

Volumn 21, Issue 5, 2012, Pages 765-775

  Moinpour, Carol M ^a   Donaldson, Gary W ^a,b   Liepa, Astra M ^c   Melemed, Allen S ^c   O'shaughnessy, Joyce ^d   Albain, Kathy S ^e  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Breast cancer; Gemcitabine; Missing data; Paclitaxel; Phase III study; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; PACLITAXEL;

ADAPTIVE BEHAVIOR; ADULT; AGED; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HUMAN; INFORMATION PROCESSING; INTERNATIONAL COOPERATION; MENTAL STRESS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADAPTATION, PSYCHOLOGICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DATA COLLECTION; DEOXYCYTIDINE; FEMALE; HEALTH STATUS INDICATORS; HUMANS; INTERNATIONALITY; MIDDLE AGED; PACLITAXEL; PAIN MEASUREMENT; PSYCHOMETRICS; QUALITY OF LIFE; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 84863632106     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-011-9999-z     Document Type: Article

References (55)

1. Bishop, J. F., Dewar, J., Toner, G. C., et al. (1999). Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. Journal of Clinical Oncology, 17(8), 2355-2364. (Pubitemid 29368233)
2. Jones, S. E., Erban, J., Overmoyer, B., et al. (2005). Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. Journal of Clinical Oncology, 23(24), 5542-5551.
3. Hakamies-Blomqvist, L., Luoma, M., Sjöström, J., et al. (2000). Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group. European Journal of Cancer, 36(11), 1411-1417. (Pubitemid 30421146)
4. O'Shaughnessy, J., Miles, D., Vukelja, S., et al. (2002). Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. Journal of Clinical Oncology, 20(12), 2812-2823. (Pubitemid 34651510)
5. Sledge, G. W., Neuberg, D., Bernardo, P., et al. (2003). Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). Journal of Clinical Oncology, 21(4), 588-592. (Pubitemid 46621890)
6. Winer, E. P., Berry, D. A., Woolf, S., et al. (2004). Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and leukemia group B trial 9342. Journal of Clinical Oncology, 22(11), 2061-2068. (Pubitemid 41095138)
7. Bernhard, J., Gusset, H., & Hürny, C. (1998). Practical issues in quality of life assessment in multicentre trials conducted by the Swiss group for clinical cancer research. Statistics in Medicine, 17(5/6/7), 633-639. (Pubitemid 28118935)
8. Moinpour, C. M., Sawyers, T. J., McKnight, B., et al. (2000). Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. Psycho-Oncology, 9(4), 340-354.
9. Fairclough, D. L. (2010). Design and analysis of quality of life studies in clinical trials, 2nd ed. Interdisciplinary statistics. Boca Raton, FL: Chapman & Hall/CRC.
10. Fayers, P. M., & Machin, D. (2000). Quality of life: Assessment, analysis, and interpretation. Chichester, United Kingdom: John Wiley & Sons Ltd.
11. Pauler, D. K., McCoy, S., & Moinpour, C. (2003). Pattern mixture models for longitudinal quality of life studies in advanced stage disease. Statistics in Medicine, 22(5), 795-809. (Pubitemid 36266967)
12. Donaldson, G. W., & Moinpour, C. M. (2005). Learning to live with missing quality-of-life data in advanced-stage disease trials. Journal of Clinical Oncology, 23(30), 7380-7384. (Pubitemid 46291794)
13. Nabholtz, J. M., Senn, H. J., Bezwoda, W. R., et al. (1999). Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. Journal of Clinical Oncology, 17(5), 1413-1424. (Pubitemid 29220847)
14. Kramer, J. A., Curran, D., Piccart, M., et al. (2000). Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist. European Journal of Cancer, 36(12), 1488-1497. (Pubitemid 30619001)
15. Nabholtz, J. M., Falkson, C., Campos, D., et al. (2003). Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results: of a randomized, multicenter, phase III trial. Journal of Clinical Oncology, 21(6), 968-975. (Pubitemid 46594123)
16. O'Shaughnessy, J., Nag, S., & Calderillo-Ruiz, G., et al. (2003). Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as firstline treatment for anthracycline pre-treated metastatic breast cancer (MBC): Interim results of a global phase III study. Proceedings of the American Society of Clinical Oncology, 22(7s), 25.
17. Albain, K., Nag, S., & Calderillo-Ruiz, G., et al. (2004). Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. Journal of Clinical Oncology, 22(14s), 510.
18. Moinpour, C. M., Wu, J., & Donaldson, G. W., et al. (2004). Gemcitabine plus paclitaxel versus paclitaxel as first-line treatment for anthracycline pre-treated metastatic breast cancer: Quality-of-life and pain palliation results from the global phase III study. Journal of Clinical Oncology, 22(14s), 621.
19. Albain, K. S., Nag, S. M., Calderillo-Ruiz, G., et al. (2008). Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. Journal of Clinical Oncology, 26(24), 3950-3957.
20. Hogan, J. W., & Laird, N. M. (1997). Mixture models for the joint distribution of repeated measures and event times. Statistics in Medicine, 16(3), 239-257. (Pubitemid 27029300)
21. Hogan, J. W., & Laird, N. M. (1997). Model-based approaches to analysing incomplete longitudinal and failure time data. Statistics in Medicine, 16(3), 259-273.
22. Nabholtz, J. M., Gelmon, K., Bontenbal, M., et al. (1996). Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. Journal of Clinical Oncology, 14(6), 1858-1867. (Pubitemid 26185461)
23. de Haes, J. C., van Knippenberg, F. C., & Neijt, J. P. (1990). Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam symptom checklist. British Journal of Cancer, 62(6), 1034-1038.
24. de Haes, J. C. J. M., Olschewski, M., Fayers, P., et al. (1996). Measuring the quality of life of cancer patients with the Rotterdam symptom checklist (RSCL). A Manual. Groningen, the Netherlands: Northern Centre for Healthcare Research, University of Groningen.
25. Cleeland, C. S., & Ryan, K. M. (1994). Pain assessment: Global use of the brief pain inventory. Annals of the Academy of Medicine, Singapore, 23(2), 129-138.
26. Hopwood, P., Howell, A., & Maguire, P. (1991). Screening for psychiatric morbidity in patients with advanced breast cancer: Validation of two self-report questionnaires. British Journal of Cancer, 64(2), 353-356.
27. Ramirez, A. J., Towlson, K. E., Leaning, M. S., et al. (1998). Do patients with advanced breast cancer benefit from chemotherapy? British Journal of Cancer, 78(11), 1488-1494. (Pubitemid 28517546)
28. Richards, M. A., Hopwood, P., Ramirez, A. J., et al. (1992). Doxorubicin in advanced breast cancer: Influence of schedule on response, survival and quality of life. European Journal of Cancer, 28(6-7), 1023-1028.
29. Cleeland, C. S., Gonin, R., Hatfield, A. K., et al. (1994). Pain and its treatment in outpatients with metastatic cancer. New England Journal of Medicine, 330(9), 592-596. (Pubitemid 24065792)
30. Twycross, R., Harcourt, J., & Bergl, S. (1996). A survey of pain in patients with advanced cancer. Journal of Pain and Symptom Management, 12(5), 273-282. (Pubitemid 26362301)
31. Collins, C., Eary, J. F., Donaldson, G., et al. (1993). Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial. Journal of Nuclear Medicine, 34(11), 1839-1844. (Pubitemid 23331244)
32. Donaldson, G. W. (1989). The determining role of theory in measurement practice. In C. R. Chapman & J. D. Loeser (Eds.), Advances in pain research and therapy: Issues in pain measurement (Vol. 12, pp. 17-35). New York, NY: Raven Press.
33. Little, R. J. A. (1993). Pattern-mixture models for multivariate incomplete data. Journal of the American Statistical Association, 88(421), 125-134.
34. Little, R. J. A. (1994). A class of pattern-mixture models for multivariate incomplete data. Biometrika, 81(3), 471-483.
35. Hedeker, D., & Gibbons, R. D. (1997). Application of randomeffects pattern-mixture models for missing data in longitudinal studies. Psychological Methods:, 2(1), 64-78. (Pubitemid 127453671)
36. Lin, H., McCulloch, C. E., & Rosenheck, R. A. (2004). Latent pattern mixture models for informative intermittent missing data in longitudinal studies. Biometrics, 60(2), 295-305. (Pubitemid 38780188)
37. Cleveland, W. S. (1985). The elements of graphing data. Monterey, CA: Wadsworth.
38. Donaldson, G. (2008). Patient-reported outcomes and the mandate of measurement. Quality of Life Research, 17(10), 1303-1313.
39. Donaldson, G. W., & Moinpour, C. M. (2002). Individual differences in quality of life treatment response. Medical Care, 40(6), III39-III53.
40. Littell, R. C., Milliken, G. A., Stroup, W. W., et al. (1996). SAS system for mixed models. Cary, NC: SAS Institute.
41. Moinpour, C. M., Donaldson, G. W., & Liepa, A. M., et al. (2007). Cumulative probability plots: A visual summary of patient benefit due to therapy. 2007 International Society for Quality of Life Research meeting abstracts [www.isoqol.org/2007mtgabstracts]. The QLR Journal, A-9
42. US Department of Health and Human Services, Food and Drug Administration. (Dec. 2009). Guidance for industry. Patientreported outcome measures: use in medical product development to support labeling claims. http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM19 3282.pdf.
43. Cohen, J. (1988). Statistical power analysis for behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum and Associates.
44. Osoba, D., Rodrigues, G., Myles, J., et al. (1998). Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology, 16(1), 139-144. (Pubitemid 28041591)
45. Geels, P., Eisenhauer, E., Bezjak, A., et al. (2000). Palliative effect of chemotherapy: Objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. Journal of Clinical Oncology, 18(12), 2395-2405. (Pubitemid 30415826)
46. Hopwood, P., Watkins, J., Ellis, P., et al. (2008). Clinical interpretation of quality-of-life outcomes: An investigation of data from the randomized trial of gemcitabine plus paclitaxel compared with paclitaxel alone for advanced breast cancer. The Breast Journal, 14(3), 228-235. (Pubitemid 351678053)
47. Goodwin, P. J., Black, J. T., Bordeleau, L. J., et al. (2003). Health-related quality-of-life measurement in randomized clinical trials in breast cancer-taking stock. The Journal of the National Cancer Institute, 95(4), 263-281. (Pubitemid 36336477)
48. Bottomley, A., & Therasse, P. (2002). Quality of life in patients undergoing systemic therapy for advanced breast cancer. The lancet Oncology, 3(10), 620-628. (Pubitemid 35174680)
49. Bernhard, J., Cella, D. F., Coates, A. S., Fallowfield, L., Ganz, P. A., Moinpour, C. M., et al. (1998). Missing quality of life data in cancer clinical trials: Serious problems and challenges. Statistics in Medicine, 17(5-7), 517-532. (Pubitemid 28118924)
50. Bernhard, J., & Gelber, R. D. [Guest Editors] (1998). Workshop on missing data in quality of life research in cancer clinical trials: Practical and methodological issues. Statistics in Medicine, 17(5-7), 511-796.
51. Singer, J. D., & Willett, J. B. (2003). Applied longitudinal data analysis: Modeling change and event occurrence. New York: Oxford University Press.
52. Little, R. J. A. (1995). Modeling the drop-out mechanism in repeated-measures studies. Journal of the American Statistical Association, 90(431), 1112-1121.
53. Rubin, D. B. (1976). Inference and missing data. Biometrika, 63(3), 581-592.
54. Laird, N. M., & Ware, J. H. (1982). Random-effects models for longitudinal data. Biometrics, 38(4), 963-974.
55. Troxel, A. B., Fairclough, D. L., Curran, D., & Hahn, E. A. (1998). Statistical analysis of quality of life with missing data in cancer clinical trials. Statistics in Medicine, 17(5-7), 653-666. (Pubitemid 28118937)